IFNA2 anticorps (Biotin)

N° du produit ABIN6963844

Cité dans 5 publications. Cet anticorps anti-IFNA2 Monoclonal Souris conjugué à Biotin (Clone MT2) (ABIN6963844) détecte spécifiquement IFNA2 dans ELISA et ELISpot. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour IFNA2 anticorps (Biotin) (ABIN6963844)

Antigène: IFNA2 (Interferon, alpha 2 (IFNA2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp IFNA2 est conjugé à/à la Biotin

Application: ELISA, ELISpot

Clone: MT2

Détail du produit anti-IFNA2 anticorps (Biotin)

Specificité: Native and recombinant human IFN-α subtypes 2a, 2b, 2c

Purification: Biotinylated through reaction with a N-hydroxysuccinimide ester of biotin.,Purified from in vitro cultures by protein G affinity chromatography.

Stérilité: 0.2 μm filtered

Immunogène: Recombinant human IFN-alpha 2c

Isotype: IgG1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: supplied at 1 mg/mL in PBS with 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store product at 4-8°C or frozen at -20°C or below. Avoid repeated freezing/ thawing.

Date de péremption: 18 months

Références pour anticorps anti-IFNA2 (Biotin) (ABIN6963844)

Yadav, McLeod, Nowell, Selby, Johnston, Kaminskas, Trevaskis: "Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery." dans: Journal of controlled release : official journal of the Controlled Release Society, Vol. 272, pp. 17-28, (2019) (PubMed).

Hochmann, Mittermeir, Santic, Koszik, Griessner, Sonderegger, Hoffmann, Russe, Scheiblhofer, Weiss, Mandler, Schneeberger, Strunk: "Evaluation of modified Interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer." dans: Scientific reports, Vol. 8, Issue 1, pp. 12954, (2019) (PubMed).

Chan, Feeney, Leong, McLeod, Porter, Williams, Kaminskas: "An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration." dans: Biomacromolecules, Vol. 18, Issue 9, pp. 2866-2875, (2018) (PubMed).

Bijak, Dziedzic, Synowiec, Sliwinski, Saluk-Bijak: "Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes." dans: Nutrients, Vol. 9, Issue 9, (2018) (PubMed).

Ingelsson, Söderberg, Strid, Söderberg, Bergh, Loitto, Lotfi, Segelmark, Spyrou, Rosén: "Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, Issue 3, pp. E478-E487, (2018) (PubMed).

Détails sur IFNA2

Antigène: IFNA2 (Interferon, alpha 2 (IFNA2))

Autre désignation: IFNA2

ID gène: 3440

Pathways: Signalistation JAK/STAT, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C